[헬스코리아뉴스 / 정우성] Naver, Korea’s leading IT company, has appointed a 41-year-old woman born in 1981 as its new CEO. The proportion of executives of listed companies born in the 1980s, who are in their 30s and 40s, is gradually increasing.
According to the
What about the pharmaceutical and biotech industries? Health Korea News conducted a complete survey of the executives of pharmaceutical, bio, and healthcare companies in the top 500 by market capitalization on the KOSPI and KOSDAQ, respectively. In particular, there were many cases in which young executives were appointed, centered on bio ventures listed on the KOSDAQ.
Hanmi Pharm and Genome & Company had the most executives born in the 1980s with five executives among the companies surveyed. Hanmi Pharm has directors Lim Ho-taek, Jeong In-ki, Kim Yu-ri, Son Min-ah, and Cho Hyung-jin. In Genome & Company, Vice President Seo Young-jin, Outside Director Nam Kwang-min, Executive Director Park Byeong-gyu, Director Yoo Seong-yeol, and Director Kim Sang-gyun were born in the 1980s.
Executives born in the 80s, active in KOSDAQ bio venture
Hpio, a health functional food company, was followed by four executives born in the 1980s. Director Kim Bo-yeon, wife of CEO Lee Hyun-yong, the largest shareholder, is also included. In addition, there are Seo Joo-won, outside director Jeong Hoon-jae, and Kim Hye-il.
Dongwha Pharm, Tium Bio, NewG Lab Pharma, Avion, and Nexton Bio each have three executives born in the 1980s. Dongguk Pharm, a former Miss Korea, is an outside director of Dongguk University’s Department of Food Science and Biotechnology, Professor Geum Nana. Managing Director In-Ho Yoon and Managing Director Hyun-Kyung Yoon are in charge of management support. Managing Director Yoon and Managing Director Yoon are the children of Dong-Wha Pharm Chairman Do-Jun Yoon.
Tium Bio is an accountant-turned-account director Jeong Jin-woo and Park Dae-woo, and pharmacist Jeon Jae-eun director. NewG Lab Pharma’s director Dae-hye Kim, outside director Yo-han Lee, and director Shin-young Han were born in the 1980s. Avion is director Hwa-Young Lee, Gyeong-Ei Park, and Na-Young Kim. Nextton Bio has CEO Bae Jun-oh, accountant Lim Hu-seop outside director, and Auditor Yoo Yu-kyun.
Kyungdong Pharmaceutical and Qrient have two executives born in the 1980s. Kyungdong Pharmaceutical is an outside director with Ryu Ki-seong, the son of Honorary Chairman Ryu Duk-hee, and Lee Sang-woo, a tax accountant. Curient, a new drug development company, has two directors, Jeong-Jun Kim and Hyun-Jung Kim.
Many executives born in the 1980s appeared to be the children of the largest shareholder. Heo Jin-seong, the head of Green Cross Holdings, is the eldest son of Green Cross Chairman Huh Il-seop. Vice President Seo Jin-seok, the eldest son of Celltrion Honorary Chairman Seo Jeong-jin, is also an executive at Celltrion and Celltrion Pharmaceuticals. Cho Hye-im, the daughter of SD Biosensor Chairman Cho Young-sik, serves as the managing director.
Director Han Sang-woo of Jeil Pharm is the second son of Chairman Han Seung-soo. The eldest son of Hana Pharmaceutical founder Cho Kyung-il, honorary chairman, is vice president Cho Dong-hoon, the largest shareholder. Baek In-hwan, managing director of Daewon Pharmaceutical, is the eldest son of Baek Seung-yeol. The daughter of Novalex CEO Kwon Seok-hyung is Kwon Soo-hye, director.
However, there are also young executives who have been recognized for their abilities. Director Park Eun-kyung of Daewoong Pharmaceutical, Director Lee Jae-hwon of Ildong Pharmaceutical, Director Seung-chan Won Won of HK Innoen Director Dae-yong Kim of HLB Life Sciences Director Ga-ram Lee of Eubiologics, Director Jeong-seok Lee of Sillajen, Director Sae-rom Kim of Medpacto, Jong-man Yoo, Director of CHA Biotech Center, Director Tae-Woo Kim of Neo-Immunetech, Eunmi Kim, Vice President of Caregen, Jinhyeong Shim, Director of T&R Biofab, Sanghee Lee, Director of Amicogen, Daehyeon Shin, Director of Prestige Biologics, Yunjeong Choi, Managing Director of Antrogen Executives born in the 1980s were named the youngest executives of the company.
Why is there such an increase in the number of executives born in the 80s? First of all, it is related to the atmosphere in which venture investment in the pharmaceutical and bio industries is revitalized. Unlike large and mid-sized pharmaceutical companies that are promoted according to the number of recruiters, it has become an atmosphere in which talent selection is possible based solely on ability. The number of cases of venture companies leaving large pharmaceutical companies to challenge new drug research has also increased. In particular, professional professionals such as accountants and lawyers provide management advice from the early days of start-ups and participate in the management even afterward.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: 헬스코리아뉴스 – 더뉴스 by www.hkn24.com.
*The article has been translated based on the content of 헬스코리아뉴스 – 더뉴스 by www.hkn24.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!